Impact of early tocilizumab administration on the progression of respiratory failure in COVID-19 patients

The optimal interval for initiating tocilizumab therapy in patients with COVID-19 (COronaVIrus Disease 2019) has not been determined. The aim of the study was to evaluate the effectiveness of prescribing tocilizumab depending on the duration of persistent hyperthermia > 38 °С in patients with SARS-CoV-2 (Severe Acute Respiratory Syndrome-related CoronaVirus 2) associated pneumonia who received tocilizumab according to the Interim Guidelines of the Ministry of Health of the Russian Federation (version at the time of inclusion in the study). Methods. A retrospective cohort study was conducted in hospitalized patients (n = 163) with SARS-CoV-2-associated pneumonia from May 2020 to May 2021. Patients were retrospectively divided into 2 groups depending on the time of tocilizumab administration: ≤ 7 days (n = 61) or ≥ 8 days (n = 102) from the disease onset. Results. Patients who received tocilizumab in the first 7 days had the lower need for CPAP (Continuous Positive Airway Pressure) therapy on day 3 after tocilizumab therapy (HR (Hazard Ratio) – 0.129 (0.039 – 0.430); p = 0.001), a higher probability of a decrease in the volume of lung lesions on computed tomography > 25% a week after the use of tocilizumab (HR – 1.065 (1.036 – 1.093); p = 0.001), the lower probability of hemoglobin oxygen saturation below 92% on day 3 (HR – 0.807 (0.750 – 0.869); p = 0.001), and day 7 (HR – 0.825 (0.772 – 0.883); p = 0.001) after tocilizumab therapy. If CPAP therapy was required on day 3 after administration of tocilizumab, each day of delay in prescribing the drug increased the risk of an adverse outcome 18-fold (HR – 18.24 (5.328 – 62.438); p = 0.001). The duration of hospitalization was significantly lower in the early group than in the late group (10 (8.5 – 15) vs 13.5 (10 – 18) days, respectively; p = 0.02). The mortality was similar (5 (8.2%) vs 6 (5.9%) patients, respectively; p = 0.748). Conclusion. The administration of tocilizumab in the first seven days from the onset of the disease in patients with COVID-19 who developed systemic inflammation and lung damage may prevent the need for escalation of respiratory support and accelerate recovery compared with the later tocilizumab administration.

1. Avdeev S.N., Tsareva N.A., Merzhoeva Z.M. et al. [Practical guidance for oxygen treatment and respiratory support of patients with COVID-19 infection before admission to intensive care unit]. Pul'monologiya. 2020; 30 (2): 15–163. DOI: 10.18093/0869-0189-2020-30-2-151-163 (in Russian).

2. Yang X., Yu Y., Xu J. et. al. Clinical course and outcomes of critically ill patients with SARS CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8 (5): 475–481. DOI: 10.1016/S2213-2600(20)30079-5.

3. Zaryanova E.A., Osipova G.L., Osipova V.V. [Respiratory viral infections, SARS-СoV-2 and chronic obstructive pulmonary disease]. Pul'monologiya. 2022; 32 (4): 616–625. DOI: 10.18093/0869-0189-2022-32-4-616-625 (in Russian).

4. Klypa T.V., Bychinin M.V., Mandel' I.A. et al. [Clinical characteristics of patients admitted to an ICU with COVID-19. Predictors of the severe disease]. Klinicheskaya praktika. 2020; 11 (2): 6–20. DOI: 10.17816/clinpract34182 (in Russian).

5. De Stefano L., Bobbio-Pallavicini F., Manzo A. et al. A “window of therapeutic opportunity” for anti-cytokine therapy in patients with coronavirus disease 2019. Front. Immunol. 2020; 11: 572635. DOI: 10.3389/fimmu.2020.572635.

6. Murthy H., Iqbal M., Chavez J.C., Kharfan-Dabaja M.A. Cytokine release syndrome: current perspectives. Immunotargets Ther. 2019; 8: 43–52. DOI: 10.2147/ITT.S202015.

7. Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46 (5): 846–848. DOI: 10.1007/s00134-020-05991-x.9.

8. Ramos-Casals M., Brito-Zeron P., Lopez-Guillermo A. et al. Adult haemophagocytic syndrome. Lancet. 2014; 383 (9927): 1503–1516. DOI: 10.1016/S0140-6736(13)61048-X.

9. Karakike E., Giamarellos-Bourboulis E.J. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front. Immunol. 2019; 10: 55. DOI: 10.3389/fimmu.2019.00055.

10. Luo P., Liu Y., Qiu L. et al. Tocilizumab treatment in COVID-19: a single center experience. J. Med. Virol. 2020; 92 (7): 814–818. DOI: 10.1002/jmv.25801.

11. Stone J.H., Frigault M.J., Serling-Boyd N.J. et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N. Engl. J. Med. 2020; 383 (24): 2333–2344. DOI: 10.1056/NEJMoa2028836.

12. Malgie J., Schoones J.W., Pijls B.G. Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin. Infect. Dis. 2021: 72 (11): e742–749. DOI: 10.1093/cid/ciaa1445.

13. Hernández-Mora M.G., Cabello Úbeda A., Prieto-Pérez L. et al. Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia. Int. J. Infect. Dis. 2021; 102: 303–309. DOI: 10.1016/j.ijid.2020.10.045.

14. Sinha P., Mostaghim A., Bielick C.G. et al. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. Int. J. Infect. Dis. 2020; 99: 28–33. DOI: 10.1016/j.ijid.2020.07.023.

15. Angriman F., Ferreyro B.L., Burry L. et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir. Med. 2021; 9 (6): 655–664. DOI: 10.1016/S2213-2600(21)00139-9.

16. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397 (10285): 1637–1645. DOI: 10.1016/S0140-6736(21)00676-0.

17. Winthrop K.L., Mariette X. To immunosuppress: whom, when and how? That is the question with COVID-19. Ann. Rheum. Dis. 2020; 79 (9): 1129–1131. DOI: 10.1136/annrheumdis-2020-218694.

18. Ministry of Health of the Russian Federation. [Temporary guidelines: Prevention, diagnosis and new treatment of coronavirus infection (COVID 19)]. Version 14 (December 27, 2021). Available at: https://xn--80aesfpebagmfblc0a.xn--p1ai/ai/doc/1213/attach/vmr_COVID-19_V14_27-12-2021.pdf (in Russian).

19. Klopfenstein T., Conrozier T., Kadiane-Oussou N.J. et al. Is there still a place for tocilizumab in Coronavirus disease 2019? Open Forum Infect. Dis. 2021; 8 (2): ofab013. DOI: 10.1093/ofid/ofab013.

20. Fisher M.J., Raymundo L.A.M., Monteforte M. et al. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients. Int. J. Inf. Dis. 2021; 103: 536–539. DOI: 10.1016/j.ijid.2020.12.021.

21. Gupta S., Wang W., Hayek S.S. et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern. Med. 2021; 181: 41–51. DOI: 10.1001/jamainternmed.2020.6252.

22. REMAP-CAP Investigators; Gordon A.C., Mouncey P.R., Al-Beidh F. et al. Interleukin-6 receptor antagonists in critically Ill patients with COVID-19. N. Engl. J. Med. 2021; 384 (16): 1491–1502. 10.1056/nejmoa2100433.

23. Mehta P., McAuley D.F., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229): 1033–1034. DOI: 10.1016/S0140-6736(20)30628-0.

24. Mariette X., Hermine O., Tharaux P.L. et al. Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial. JAMA Intern. Med. 2021; 181 (9): 1241–1243. DOI: 10.1001/jamainternmed.2021.2209.

25. WHO rapid evidence appraisal for COVID-19 Therapies (REACT) working group; Shankar-Hari M., Vale C.L., Godolphin P.J. et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021; 326 (6): 499–518. DOI: 10.1001/jama.2021.11330.

26. Caricchio R., Gallucci M., Dass C. et al. Preliminary predictive criteria for COVID-19 cytokine storm. Ann. Rheum. Dis. 2021; 80 (1): 88–95. DOI: 10.1136/annrheumdis-2020-218323.

27. Durán-Méndez A., Aguilar-Arroyo A.D., Vivanco-Gómez E. et al. Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study. Sci. Rep. 2021; 11 (1): 19728. DOI: 10.1038/s41598-021-99291-z.

28. Rubio-Rivas M., Forero C.G., Mora-Luján J.M. et al. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis. Pharmacotherapy. 2021; 41 (11): 884–906. DOI: 10.1002/phar.2627.

29. Moreno Diaz R., Amor García M.A., Teigell Muñoz F.J. et al. Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19. Eur. J. Hosp. Pharm. 2022; 29 (6): 340–345. DOI: 10.1136/ejhpharm-2020-002669.

30. Khiali S., Entezari-Maleki T. Tocilizumab in COVID-19 management: addressing time of starting treatment. Eur. J. Hosp. Pharm. 2023; 30 (2): e9. DOI: 10.1136/ejhpharm-2021-003149.

31. Moiseev S., Avdeev S., Tao E. et al. Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study. Ann. Rheum. Dis. 2023; 82 (1): e3. DOI: 10.1136/annrheumdis-2020-219265.

32. Fomina D.S., Poteshkina N.G., Beloglazova I.P. et al. [Comparative analysis of tocilizumab in severe COVID-19-associated pneumonia in patients of different age groups]. Pul'monologiya. 2020; 30 (2): 164–172. DOI: 10.18093/0869-0189-2020-30-2-164-172 (in Russian).

33. Nuñez-Ramos J.A., Forero Illera E., Quintero Barrios J.L. et al. Prognostic factors in hospitalized COVID-19 patients at the start of the pandemic in Colombia: a retrospective cohort study. Cureus. 2021; 13 (5): e14865. DOI: 10.7759/cureus.14865.

34. Kruglova T.S., Fomina D.S., Poteshkina N.G. et al. [Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19]. Terapevticheskiy arkhiv. 2021; 93 (11): 1316–1324. DOI: 10.26442/00403660.2021.11.201248 (in Russian).

35. Mohiuddin Chowdhury A.T.M., Kamal A., Abbas K.U. et al. Efficacy and outcome of remdesivir and tocilizumab combination against dexamethasone for the treatment of severe COVID-19: a randomized controlled trial. Front. Pharmacol. 2022; 13: 690726. DOI: 10.3389/fphar.2022.690726.